Business Wire

NC-PERCONA

17.5.2022 18:06:05 CEST | Business Wire | Press release

Share
Percona Announces General Availability of Percona Platform

Percona , a leader in open source database software and services, today announced the general availability of Percona Platform , which brings the company’s expertise with databases including MySQL®, PostgreSQL® and MongoDB® together alongside services, management and automated insights into a single product. Using the company’s experience in managing and improving some of the largest database installations in the world, Percona Platform helps users monitor, manage, secure and optimize their database instances across any infrastructure.

“Percona Platform brings the experience and expertise that we have built up over the years and puts it in the hands of developers and database administrators to use. It includes AI-powered recommendations that help users improve performance, management and security, as well as making it easier to scale up and manage their instances over time. With Percona Platform, we thought about how to improve the experience for developers and DBAs around running their data workloads, and how to help people achieve their goals faster around managing databases as part of their overall approach,” said Donnie Berkholz, Senior Vice President Product at Percona.

“Developers want to improve their efficiency and experience across their tasks, and databases are no exception. Improving this will be an area of investment for companies - whether this involves time for their staff to implement projects, or investing in cloud services to provide the tools they need. Percona’s approach to this challenge aims to provide self-managed control and internal ownership as well as the flexibility and ease of use that many companies tout with their DBaaS offerings. By offering a fully open source compatible service, Percona is looking to plug a gap in the market that many database companies are not able to cover,” commented Bradley Shimmin, Chief Analyst, AI platforms, analytics and data management at Omdia.

“There has been an explosion of data tools available to enterprises, which in turn has led to rampant fragmentation and highly complex, disjointed workflows. Organizations that prize velocity are looking for ways to integrate various data tools into their broader development workflows and monitor them. This is the opportunity that Percona Platform is built for. The combination of software and services in this space is intended to help customers better manage their database deployments,” commented Rachel Stephens, Senior Analyst, RedMonk.

“Percona has woven over a decade of open-source database expertise into a consistent, modern database experience for all organizations, from any cloud to on-premises. With Percona Platform we have built out our open source database software offerings, bolstered by automated insights, self-service operations, and the best database observability and management tools in the market. This launch will help us scale our business and create a sustainable model in the age of cloud, while respecting the freedom and accessibility that is open source. We have seen other companies turn away from open source and adopt closed source licenses in order to maximize their profitability, which we think is not in the best interests of customers. Our approach makes our expertise available to all our customers and users, putting their needs first,” added Ann Schlemmer, President at Percona.

Percona Platform is the culmination of the company’s work to expand and deliver its wide-ranging knowledge of databases into products that users can deploy quickly and use to improve their performance. As part of the launch, Percona has used its service expertise to create automated recommendation products called Advisors for customers that can help them immediately improve their results. It supports all deployment configurations, from public, private and hybrid cloud instances through to internal data center deployments. It supports both self-managed and Percona-managed instances, letting customers approach their database management in the way that suits them.

Percona Platform includes the following elements:

  • Percona Portal - access to all Percona services and product expertise through one unified online portal, covering multiple databases with enterprise-level features including backup, security, management, optimization and more
  • Percona Monitoring and Management (PMM) - a database management product that is fully open source itself, allowing developers and DBAs to streamline their management tasks across multiple platforms from one place
  • New range of Advisors - automated insights that ensure user databases are performing at their best, including security management, configuration and performance improvements
  • Private DBaaS Technical Preview - this will support companies deploying their own DBaaS internally using open source database distributions, Percona management tool PMM and Kubernetes operators for MySQL and PostgreSQL. It will also support the same approach for MongoDB. This enables users to easily provision and manage database instances on a self-service basis across development and testing instances, improving the experience for developers
  • Percona Account - simplified user account management for all Percona products and services under one account

Links

About Percona

Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.

Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, and Rent the Runway, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. For more information, visit www.percona.com .

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye